Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; AbbVie for the discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106; and Evotec AG for the novel target for fibrosis and other indications. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone321-534-2900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$176.13 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableOptionable
GALAPAGOS NV/S (NASDAQ:GLPG) Frequently Asked Questions
What is GALAPAGOS NV/S's stock symbol?
GALAPAGOS NV/S trades on the NASDAQ under the ticker symbol "GLPG."
What price target have analysts set for GLPG?
13 equities research analysts have issued 12 month price objectives for GALAPAGOS NV/S's stock. Their forecasts range from $90.00 to $157.00. On average, they anticipate GALAPAGOS NV/S's share price to reach $125.10 in the next twelve months. This suggests a possible upside of 22.2% from the stock's current price. View Analyst Price Targets for GALAPAGOS NV/S.
What is the consensus analysts' recommendation for GALAPAGOS NV/S?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GALAPAGOS NV/S in the last year. There are currently 2 hold ratings, 10 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GALAPAGOS NV/S.
Has GALAPAGOS NV/S been receiving favorable news coverage?
Headlines about GLPG stock have been trending somewhat positive on Wednesday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. GALAPAGOS NV/S earned a coverage optimism score of 1.7 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days.
Who are some of GALAPAGOS NV/S's key competitors?
Some companies that are related to GALAPAGOS NV/S include Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Ono Pharmaceutical (OPHLF), Mylan (MYL), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Ionis Pharmaceuticals (IONS), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ) and SAGE Therapeutics (SAGE).
What other stocks do shareholders of GALAPAGOS NV/S own?
Who are GALAPAGOS NV/S's key executives?
GALAPAGOS NV/S's management team includes the folowing people:
- Mr. Onno van de Stolpe, Co-Founder, MD, CEO & Exec. Director (Age 60)
- Mr. Bart Filius MBA, CFO & COO (Age 49)
- Dr. Piet Wigerinck, Chief Scientific Officer (Age 55)
- Ms. Elizabeth Goodwin, VP of Investor Relations & Corp. Communications
- Dr. Andre Hoekema, Chief Bus. Officer (Age 62)
When did GALAPAGOS NV/S IPO?
(GLPG) raised $161 million in an initial public offering (IPO) on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.
Who are GALAPAGOS NV/S's major shareholders?
GALAPAGOS NV/S's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (0.72%), BlackRock Inc. (0.62%), Bank of New York Mellon Corp (0.49%), Peregrine Capital Management LLC (0.17%), Alps Advisors Inc. (0.15%) and Millennium Management LLC (0.14%).
Which major investors are selling GALAPAGOS NV/S stock?
GLPG stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Jane Street Group LLC, BlackRock Inc., Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp, Dorsey Wright & Associates, Alps Advisors Inc., Castleark Management LLC and Stifel Financial Corp.
Which major investors are buying GALAPAGOS NV/S stock?
GLPG stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Norges Bank, Prosight Management LP, OLD Mission Capital LLC, D. E. Shaw & Co. Inc., Victory Capital Management Inc., Millennium Management LLC and FNY Investment Advisers LLC.
How do I buy shares of GALAPAGOS NV/S?
Shares of GLPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GALAPAGOS NV/S's stock price today?
One share of GLPG stock can currently be purchased for approximately $102.39.
How big of a company is GALAPAGOS NV/S?
GALAPAGOS NV/S has a market capitalization of $5.25 billion and generates $176.13 million in revenue each year. The biotechnology company earns $-130,780,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis.
What is GALAPAGOS NV/S's official website?
How can I contact GALAPAGOS NV/S?
GALAPAGOS NV/S's mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company can be reached via phone at 321-534-2900 or via email at [email protected]
MarketBeat Community Rating for GALAPAGOS NV/S (NASDAQ GLPG)
MarketBeat's community ratings are surveys of what our community members think about GALAPAGOS NV/S and other stocks. Vote "Outperform" if you believe GLPG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLPG will underperform the S&P 500 over the long term. You may vote once every thirty days.
